Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $15.7M fell 8.5% year over year, ahead of the -17.5% change in trailing-twelve-month research & development. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -8.5% holds above the trailing-twelve-month pace of -17.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 63.8M USD
- Year-over-year change
- -13.9%
- 4-year CAGR
- +9.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.8M | -13.9% |
| FY2024 | 2024-12-31 | 74.09M | +39.5% |
| FY2023 | 2023-12-31 | 53.13M | +8.1% |
| FY2022 | 2022-12-31 | 49.16M | +9.0% |
| FY2021 | 2021-12-31 | 45.12M | — |
Research & Development vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's LTM Mar 2026 research & development of $62.33M is the 7th highest of the 11 companies compared; the peer median is $97.45M.
- Its year-over-year change of -17.5% is the lowest of 10, against a peer median of +11.3%.
- Over three fiscal years its annual growth of +9.1% compares with a peer median of +27.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.7M | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $126.01M | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $124.71M | +42.2% | +15.6% | — | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M | -17.5% | +9.1% | — |
| LTM Mar 2026 | $61.84M | — | +24.0% | 6710.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M | +11.3% | +45.0% | — |
| LTM Mar 2026 | $18.45M | -6.9% | -13.3% | 8.6% | |
| LTM Mar 2026 | $18.13M | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding LXEO) | $97.45M | +11.3% | +27.2% | 350.1% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.66M | 654K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.66M | 654K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 45.12M | 49.16M | 53.13M | 74.09M | 63.8M |
| Selling, General & Admin | 7.17M | 12M | 15.38M | 31.68M | 45.46M |
| Operating Expenses | 52.29M | 61.16M | 68.51M | 105.77M | 109.26M |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 2.08M |
| EBITDA | (50.61M) | (58.04M) | (64.35M) | (96.19M) | (97.68M) |
| EBITDA Margin | -3054.3% | -8874.8% | — | — | — |
| Operating Income | (50.64M) | (60.51M) | (68.51M) | (105.77M) | (109.26M) |
| Operating Margin | -3055.9% | -9252.1% | — | — | — |
| Interest Income | 15K | 1.33M | 2.87M | 7.56M | 6.13M |
| Interest Expense | 0 | 91K | 205K | 114K | 206K |
| Other Income / Expenses | 15K | 1.23M | 2.12M | 7.43M | 9.3M |
| Income Before Tax | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Pre-Tax Margin | -3055.0% | -9063.8% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Net Margin | -3055.0% | -9063.8% | — | — | — |
| EPS (Basic) | (2.01) | (2.36) | (2.49) | (3.09) | (1.86) |
| EPS (Diluted) | (2.01) | (2.40) | (2.49) | (3.09) | (1.86) |
| Weighted Avg Shares | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
| Weighted Avg Shares (Diluted) | 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.